. Purpose: This study aimed to determine the effects of 5 months of ovarian hormone suppression in premenopausal women on objectively measured physical activity (PA). Methods: Participants (age, 35 T 8 yr; body mass index, 27 T 6 kgIm j2 ) received monthly intramuscular injections of gonadotropin-releasing hormone agonist (GnRH AG ) therapy, which suppresses pituitary gonadotropins and results in suppression of ovarian sex hormones. Women were randomized to receive concurrent transdermal E 2 (GnRH AG + E 2 ; n = 30) or placebo (GnRH AG + PL, n = 31). PA was assessed for 1 wk before and during each month of the 5-month intervention using a hipworn accelerometer (Actical, Mini Mitter Co., Inc., Bend, OR). Estimates of time spent in sedentary, light, and moderate-to-vigorous PA (MVPA) were derived using a previously published equation. Subsets of participants in each group were also randomized to a supervised progressive resistance exercise training program. Results: Total MVPA tended toward being higher (P = 0.08) in the GnRH AG + E 2 group at month 4. There were no significant effects of intervention or time in sedentary or light PA. In the subset of women who did not participate in structured exercise training for which Actical data were obtained (n = 16 in each group), total MVPA was higher at month 4 (P = 0.01). Conclusions: PA levels seem to be maintained at a higher level in women undergoing pharmacological suppression of ovarian function with E 2 add-back when compared with women treated with placebo. These data provide proof-of-concept data that E 2 contributes to the regulation of PA in humans. However, given the exploratory nature of this study, future confirmatory investigations will be necessary. Key Words: HUMANS, ESTROGENS, RESISTANCE EXERCISE, GONADOTROPIN-RELEASING HORMONE, EFFECTS OF SEX STEROIDS P reclinical studies have demonstrated that the loss of estradiol (E 2 ) or disruption of E 2 signaling causes excess fat gain in female rodents, particularly in abdominal regions (1-4). In ovariectomized animals, this is prevented by E 2 treatment (5). Similarly, suppression of gonadal function by gonadotropin-releasing hormone agonist (GnRH AG ) therapy in humans causes excess fat gain (6-10) with abdominal fat accrual (11). In both women (11) and men (8), limited evidence indicates that such changes are specifically related to E 2 deficiency. One mechanism that may contribute to excess fat gain in response to E 2 suppression is a reduction in energy expenditure (EE). In animals, the gain in fat mass resulting from loss of E 2 or E 2 signaling has been associated with decreases in both resting (REE) and total EE (TEE) (12-16). In premenopausal women, we have previously shown that acute (6 d) and chronic (5 months) suppression of ovarian hormones caused decreases in REE (17,18) and TEE (18), and the decrease in REE was prevented by E 2 treatment (18).
P reclinical studies have demonstrated that the loss of estradiol (E 2 ) or disruption of E 2 signaling causes excess fat gain in female rodents, particularly in abdominal regions (1) (2) (3) (4) . In ovariectomized animals, this is prevented by E 2 treatment (5) . Similarly, suppression of gonadal function by gonadotropin-releasing hormone agonist (GnRH AG ) therapy in humans causes excess fat gain (6) (7) (8) (9) (10) with abdominal fat accrual (11) . In both women (11) and men (8) , limited evidence indicates that such changes are specifically related to E 2 deficiency. One mechanism that may contribute to excess fat gain in response to E 2 suppression is a reduction in energy expenditure (EE). In animals, the gain in fat mass resulting from loss of E 2 or E 2 signaling has been associated with decreases in both resting (REE) and total EE (TEE) (12) (13) (14) (15) (16) . In premenopausal women, we have previously shown that acute (6 d) and chronic (5 months) suppression of ovarian hormones caused decreases in REE (17, 18) and TEE (18) , and the decrease in REE was prevented by E 2 treatment (18) .
The decrease in TEE with loss of E 2 or disruption in E 2 signaling is due, in part, to a decline in spontaneous physical activity (SPA) and the associated EE. Both ovariectomy (3, 19) and the disruption of E 2 receptor signaling (4) in rodents cause a dramatic decline in SPA that is fully rescued by E 2 treatment (20) . However, the effects of E 2 on physical activity (PA) in humans have not been extensively explored. In National Health and Nutrition Examination Survey III, the prevalence of women reporting being physical inactive was lower in women who ever used hormone therapy (HT: 28.5%) when compared with those who had never used HT (40.0%) (21) . We are aware of only one study that obtained objective measures of PA across the menopause transition; in that study, PA at the time of menopause decreased by approximately 50% compared with 3-4 yr before menopause (22) . However, whether the decline in PA was related to the loss of E 2 , or instead biological aging or other factors associated with the menopausal transition could not be determined.
The goal of this study was to determine the effects of 5 months of ovarian hormone suppression in the absence or presence of E 2 add-back on objectively measured PA. Because PA was an exploratory outcome in the parent trial, which evaluated changes in adiposity, REE, and TEE (11, 18) , the study was not powered to detect changes in PA. Therefore, these data represent a proof-of-concept investigation to evaluate whether ovarian hormone suppression is associated with a decrease in free-living PA, as occurs in rodents.
METHODS
Institutional approval. This study was approved by the Colorado Multiple Institutional Review Board and the Scientific Advisory and Review Committee at the University of Colorado Anschutz Medical Campus. The study was registered on ClinicalTrials.gov (NCT00687739) on May 28, 2008.
Participants and screening procedures. Participants were healthy premenopausal women. Volunteers provided written informed consent to participate, with the knowledge that the risks of the study included menopause-like effects (e.g., weight gain, bone loss, and menopausal symptoms). Volunteers underwent screening procedures, as previously described (11, 18) . Primary inclusion criteria were age (25-49 yr) and normal menstrual cycle function (no missed cycles in previous year, cycle length of 28 T 5 d, and confirmation of ovulatory status (ClearPlan Easy; Unipath Diagnostics, Waltham, MA)). Primary exclusion criteria were pregnancy or lactation; use of hormonal contraception, oral glucocorticoids, or diabetes medications; smoking; or body mass index (BMI) of 939 kgIm j2 . Experimental design and study procedures. The parent trial was a randomized, double-blinded, placebocontrolled trial to determine the effects of E 2 deficiency on body composition and components of EE (11, 18) . All participants underwent suppression of ovarian sex hormones with GnRH AG therapy (leuprolide acetate 3.75 mg, Lupron; TAP Pharmaceutical Products, Inc, Lake Forest, IL), delivered as monthly intramuscular injections. A single injection of leuprolide acetate produces an initial stimulation (for 1-3 wk) followed by a prolonged suppression of pituitary gonadotropins, and repeated monthly dosing suppresses ovarian hormone secretion (23) . Absence of pregnancy (urine test) was confirmed before each dosing. Participants were randomized to receive concurrent transdermal E 2 0.075 mgId j1 (Bayer HealthCare Pharmaceuticals, Berkeley, CA) or placebo patches (GnRH AG + E 2 , n = 35; GnRH AG + PL, n = 35). During these monthly visits, participants met with the research nurse practitioner. Participants were queried about changes in use of medications or health (e.g., doctor visits and hospitalizations), as well as any study-related problems/ concerns over the past 4 wk. Compliance to the transdermal patches was confirmed verbally each month during the monthly examination. The E 2 regimen was expected to maintain serum E 2 concentrations in the mid-to-late follicular phase range (100-150 pgImL j1 ).
As previously described (11, 18) , some participants in each drug group in the parent study were also randomized to a supervised progressive resistance exercise training program (N = 12 in each group) to attenuate the expected decrease in fat-free mass with GnRH AG therapy. Not all those randomized to exercise were willing to participate in the exercise program and were therefore treated as nonexercisers for the analyses herein. The progressive resistance exercise intervention consisted of 4 dIwk j1 for 18 wk beginning in week 1 of sex hormone suppression (11) .
PA. PA was assessed using a hip-worn accelerometer (Actical; Mini Mitter Co., Inc., Bend, OR). Sampling was performed at 32 Hz and data were stored in 1-min epochs. The monitor measures accelerations in multiple planes but is most sensitive to vertical movements of the torso when worn on the hip. The resulting raw output is activity counts, which represent both the summed quantity and magnitude of accelerations during each epoch. PA was assessed for 1 wk before the intervention and for 1 wk of each month of the 5-month intervention. Participants were instructed to wear the Actical at all times for 7 consecutive days, except when engaged in water activities (e.g., bathing, showering, or swimming) or sleeping. To be included in the final analysis, 4 d of valid data was required for each time point. A day was considered valid if there was at least 10 h of wear time.
Estimates of time spent in sedentary, light, and moderateto-vigorous activity (MVPA) were derived using thresholds for number of accelerometer activity counts accumulated in a given epoch for the Actical in middle-age adults (24) . To assess whether the levels of MVPA met the 2008 Guidelines for Physical Activity in Americans (25), we examined the number of bouts lasting at least 10 min in duration with 980% of the bout categorized as MVPA (guideline MVPA) (25) . Guideline MVPA was calculated as both minutes per day (total minutes per day spent in MVPA bouts) and the number of bouts per day (the number of MPVA bouts per day). For participants in the nonexercise groups, we also determined the amount of time spent in SPA, defined as all minutes spent in light PA or MVPA performed in bouts lasting less than 10 min.
Sex hormones. Blood samples for sex hormones were collected during baseline testing and during week 20 of the intervention. A single sample (~5 mL) was obtained in the morning (~8 AM), after an overnight fast (at least 10 h), and at least 48 h after the last bout of exercise. Baseline samples were obtained immediately before the first injection. Collection samples were stored at j80-C until analysis. E 2 , progesterone, and total testosterone were analyzed using chemiluminescence immunoassay with intraday and interday coefficients of variation of 4.3% and 8.2% for E 2 , 4.4% and 7.9% for progesterone, 3.6% and 5.7% for sex hormone-binding globulin (SHBG), and 2.1% and 5.1% for total testosterone (Access 2 Immunoassay System Analyzer; Beckman Coulter, Fullerton, CA).
Statistical analysis. Baseline characteristics are presented as mean (SD) by group. Changes in these characteristics in response to the intervention are presented as mean (95% confidence interval (CI)). The primary analysis evaluated differences in time spent in sedentary behavior and in light PA and MVPA between the GnRH AG + PL and GnRH AG + E 2 groups using a repeated-measures maximum likelihood and cell means model regressing activity levels on group and time, controlling for baseline, using all available data. This approach is similar to a repeated-measures ANCOVA, but has the advantage of not requiring casewise deletion of cases missing information at one or more time points. To minimize the number of statistical tests, we estimated the overall group difference, the overall time effect, and the difference between groups at the month 4 time point. This time point was chosen because it was the last full month of the exercise intervention; participants in the exercise intervention stopped exercising 2 wk before the follow-up assessments at month 5 to allow body weight and other metabolic outcomes to stabilize before the postintervention assessments.
Because participation in the supervised exercise program could have influenced PA performed outside of the programmed exercise time, we also evaluated the effects of the intervention on the subset of women in each group who did not participate in the supervised exercise program. The maximum number of participants with valid PA data was 16 per group at visit 2; the minimum was 11 GnRH AG + E 2 and 14 GnRH AG + PL at visit 6. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). Data are reported as mean (SD) or mean (95% CI), unless otherwise specified.
RESULTS
Descriptive characteristics of participants in the GnRH AG + E 2 (N = 31) and GNRH AG + PL (N = 30) groups who had any PA data (61 of 70 participants in the parent trial) are shown in Table 1 . At baseline, the groups were similar in age, weight, BMI, and body composition. As in the larger cohort (11), fatfree mass decreased over 5 months in the GnRH AG + PL but not the GnRH AG + E 2 group; no significant changes in weight, BMI, or fat mass were observed in either group over this time frame (11) . Changes in sex steroid hormones were similar to those observed in the larger cohort. E 2 decreased in GnRH AG + PL (from 85.6 T 41.2 to 21.8 T 8.5 pgImL j1 ; P G 0.001) and increased in GnRH AG + E 2 (61.7 T 46.5 to 99.2 T 93.2 pgImL j1 ; P = 0.09). Although we did not reach target, response to E2 add-back was highly variable. Nonetheless, the between-group changes were significant. Progesterone and testosterone decreased in both groups (all P G 0.03), whereas SHBG decreased only in GnRH AG + PL (P G 0.01).
Minutes spent in sedentary behavior and in different levels of PA for all women is shown in Table 2 . Sedentary time decreased (P = 0.02), but MVPA (P = 0.03; Fig. 1 ) and ) recorded in sedentary behavior, light PA, and MVPA; guideline MVPA (total minutes spent in MVPA during bouts Q10 min); number of guideline bouts; and SPA (total minutes spent in light or MVPA performed in bouts lasting G10 min). SPA (P = 0.01; Fig. 2 ) increased in both groups during the intervention. At month 4, there were no differences between groups in sedentary time or SPA, but MVPA tended toward being higher in the GnRH AG + E 2 group. There were no significant effects of intervention or time in light PA, guideline MVPA, or the number of guideline MVPA bouts. PA data for the 28 women who did not participate in the supervised exercise program are presented in Table 3 . Actical data on 16 nonexercising participants in each group were obtained. No significant time effects were observed in any of the PA outcomes. Total time in MVPA (Fig. 3) tended toward being higher in GnRH AG + E 2 (P = 0.07) compared with GnRH AG + PL, but there were no group differences in any other measure. At month 4, MVPA (P = 0.01) and SPA (P = 0.01) were significantly higher in GnRH AG + E 2 .
Month of Intervention

DISCUSSION
Studies in animals (1,2,4,16) and humans (6-11) provide clear evidence that loss of estrogen leads to weight gain and accumulation of central fat (11) . Although the mechanisms contributing to these changes in body fat mass and distribution are not entirely understood, studies of rodents have demonstrated that E 2 signaling may play an important role in regulating SPA (3, 16, 19, 20) . However, isolating the effects of E 2 on PA in humans is very challenging. In this preliminary investigation, we demonstrated that although women in the GnRH AG + PL and GnRH AG + E 2 treatment arms had similar levels of PA at baseline and at 1 month, women in the GnRH AG + E 2 group had higher levels MVPA during months 2-5 of treatment ( Figs. 1 and 2 ). This divergence coincides with the time frame at which GnRH AG treatment would be expected to be exerting maximal effects to suppress ovarian function. A single injection of leuprolide acetate produces an initial stimulation of GnRH (for up to 3 wk) followed by a prolonged suppression of anterior pituitary gonadotropins and gonadal sex steroids. Repeated monthly dosing maintains ovarian hormone suppression. We observed similar trends in MVPA when women who were not randomized to the supervised exercise program were analyzed separately. Because this study was not powered on PA outcomes, positive or negative findings should be interpreted cautiously. Nonetheless, these data provide the first proof-of-concept evidence that E 2 status may contribute to the regulation of PA in women as it does in rodents.
Although the mechanism is not completely understood, some studies suggest that E 2 influences PA via ER>-mediated alterations in dopaminergic activity and function (26) . Although some evidence exists that PA declines across the menopause (23) and that PA is higher in women using HT (21) , convincing evidence in humans is lacking. The latter study was limited by the use of self-report instruments to measure PA as well as the variety of HT regimens used by participants, which prevented the specific effects of E 2 to be determined. The best evidence to date supporting a role of sex steroids in regulating PA in humans comes from the study of Lovejoy et al. (22) . Premenopausal women (N = 103) who were approaching menopause were studied annually for 4 yr. Menopausal status was confirmed by cessation of menstruation and follicle-stimulating hormone concentrations of Q30 mIUImL j1 . Accelerometer counts dropped by~50% over the 4 yr before postmenopausal status was confirmed. However, it was still not possible to isolate the specific effects of E 2 on PA. In this study, we show that in women who are undergoing suppression of ovarian function, replacing E 2 is associated with maintenance of higher levels of PA compared with women treated with placebo.
Although the PA outcomes in this study were designed to be exploratory, the randomized controlled study-design, double-blinding, robust pharmacological approach to control the sex steroid milieu, and the objective monitoring of PA are strengths that lend support to our conclusions. The conclusions should also be interpreted in light of several limitations. First, monitoring PA using a monitor worn on the hip is not well suited for distinguishing sedentary FIGURE 2-SPA in participants randomized to GnRH AG plus addback of placebo (GnRH AG + PL, N = 31) or E 2 (GnRH AG + E 2, N = 30). SPA tended toward being higher in GnRH AG + E 2 (P = 0.08), but there were no differences between groups at month 4 time point. BL, baseline.
behavior. Devices worn on the thigh are more sensitive to posture and perform better in classifying sedentary behavior (27) . However, these devices were not widely available when this study was conceived. Thus, it is possible that there were differences between treatment arms in the allocation between sedentary behavior and light physical activities that were not detected. Second, GnRH AG therapy does not completely reflect the changes that occur during the natural menopause transition. GnRH AG results in a more abrupt suppression of sex hormones than menopause, and gonadotropins are suppressed rather than elevated. It should be noted that there was a wide range in response to the E 2 addback therapy. We targeted mid-to-late follicular phase concentrations (100-150 pgImL j1 ), and mean E 2 concentrations in the GnRH AG + E 2 group at month 5 was 99 T 93 pgIdL j1 . However, mean E 2 concentrations at month 5 in the GnRH AG + PL group was 21 T 9 pgImL j1 . Thus, although the mean E 2 concentrations were slightly below the targeted concentrations, the mean E 2 concentrations in the two groups at 5 months differed substantially. Finally, our study was limited to women, and whether E 2 would have similar effects on PA in men is not known. Such investigations are warranted given the findings that E 2 also contributes to body fat regulation in men (8) . In that study, suppressing gonadal function in men combined with aromatase inhibition to suppress estrogen synthesis caused an increase in visceral fat, whereas suppression of gonadal function without aromatase inhibition had no effect on visceral fat. The mechanisms contributing to this gain in fat in men with E 2 suppression have not been elucidated.
CONCLUSIONS
The results of this proof-of-concept study provide support for the hypothesis that PA levels are maintained at a higher level in women undergoing pharmacological suppression of ovarian function with E 2 add-back when compared with women treated with placebo add-back. This provides the first preliminary evidence for the regulation of PA by E 2 in women. Given the exploratory nature of this study, confirmatory investigations will be necessary.
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